These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20522381)

  • 1. RANK and RANKL expression in giant-cell tumour of bone.
    Roux S; Mariette X
    Lancet Oncol; 2010 Jun; 11(6):514. PubMed ID: 20522381
    [No Abstract]   [Full Text] [Related]  

  • 2. RANK signalling in bone lesions with osteoclast-like giant cells.
    Won KY; Kalil RK; Kim YW; Park YK
    Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway.
    Jiang ZY; Jiang JJ; Ma YS; Li HY; Shi W; Fu PL; Xu CF; Lu JZ; Fu D; Xu JG
    Biochem Biophys Res Commun; 2018 Nov; 505(4):1003-1009. PubMed ID: 30309658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
    Cowan RW; Singh G; Ghert M
    J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
    Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
    J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone.
    Roux S; Amazit L; Meduri G; Guiochon-Mantel A; Milgrom E; Mariette X
    Am J Clin Pathol; 2002 Feb; 117(2):210-6. PubMed ID: 11863217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
    Wang J; Chen TY; Qin S; Duan Y; Wang G
    Med Hypotheses; 2013 Nov; 81(5):805-6. PubMed ID: 24074896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progestogens and risk of breast cancer: a link between bone and breast?
    González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
    Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
    Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
    Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
    Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
    Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone metastasis: can osteoclasts be excluded?
    Martin TJ; Mundy GR
    Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL signaling in bone physiology and cancer.
    Dougall WC
    Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
    Dougall WC; Chaisson M
    Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.